Ecstasy, legal highs and designer drug use: A Canadian perspective

  title={Ecstasy, legal highs and designer drug use: A Canadian perspective},
  author={Alan L. Hudson and Maggie D. Lalies and Glen B. Baker and Kristopher Wells and Katherine J. Aitchison},
  journal={Drug Science, Policy and Law},
Recreational drug use in Canada is not uncommon, but as with most societies, illegal drug use carries harsh penalties resulting in a criminal record when an individual is successfully prosecuted. Popular drugs of use in Canada include ecstasy, cannabis (including some synthetic cannabinoids sold as ‘Spice’ and ‘Incense’) and several emerging psychoactive ‘legal highs’. Surprisingly, Canada is a major manufacturer and exporter of the popular club drug ecstasy, with criminal gangs organising the… 

Figures from this paper

MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults

MDMA for the Treatment of Negative Symptoms in Schizophrenia

This review provides a rationale for the use of MDMA in the treatment of negative symptoms by reviewing the literature on negative symptoms, their treatment, MDMA, and MDMA-assisted therapy and concludes with considerations regarding safety and possible mechanisms of action.

Potentiel criminalistique de l'étude du trafic de drogues au Canada à partir des données collectées sur les cryptomarchés

A critical analysis of existing criminological studies suggests a forensic support to better understand the virtual world in which users operate and the use of drug profiling as a way to obtain objective empirical data, as a means of offsetting uncertainty about virtual data.



Qualitative Review of Serotonin Syndrome, Ecstasy (MDMA) and the use of Other Serotonergic Substances: Hierarchy of Risk

The study aimed to synthesize the risk of serotonin syndrome associated with the concomitant use of ecstasy and other serotonergic substances in a clinically relevant hierarchy for psychiatrists and other medical practitioners.

Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery

  • D. Nutt
  • Political Science
    Therapeutic advances in psychopharmacology
  • 2011
Last year saw the banning of several new synthetic stimulant drugs and many of their analogues, but it now seems that mephedrone was probably one of the least harmful stimulants, being less potent than most alternatives.

Ecstasy (MDMA): a review of its possible persistent psychological effects

There is growing evidence that chronic, heavy, recreational use of ecstasy is associated with sleep disorders, depressed mood, persistent elevation of anxiety, impulsiveness and hostility, and selective impairment of episodic memory, working memory and attention.

Agony and ecstasy: a review of MDMA effects and toxicity

Clinical toxicology of newer recreational drugs

The available information on newer synthetic stimulant, entactogenic and hallucinogenic drugs are reviewed, a framework for classification of these drugs based on chemical structure is provided and their pharmacology and clinical toxicology are described.

Effects of Schedule I drug laws on neuroscience research and treatment innovation

An important and unfortunate outcome of the controls placed on these and other psychoactive drugs is that they make research into their mechanisms of action and potential therapeutic uses difficult and in many cases almost impossible.

Recreational bupropion abuse in a teenager.

  • J. McCormick
  • Medicine, Psychology
    British journal of clinical pharmacology
  • 2002
A 13-year old Caucasian girl with a past history of deliberate illicit drug ingestion and evidence of a conduct disorder and mood upset symptoms was admitted to the paediatric ward after intentionally swallowing four bupropion tablets that were supplied by a friend.

Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms

Cathinone derivatives: a review of their chemistry, pharmacology and toxicology.

  • J. Kelly
  • Biology
    Drug testing and analysis
  • 2011
It can be assumed that, despite their illegal status, cathinone-related compounds will continue to be prevalent drugs of abuse for the foreseeable future.

Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States

The emergence of a new group of substances of abuse in the USA, known as bath salts, is reported with quantitative results in 18 patients, the first report of MDPV exposures with quantitative blood level confirmation.